



Vaccines and Global Health: The Week in Review
19 July 2025 :: Issue 808
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

- :: [Milestones, Perspectives](#)
- :: [WHO](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)
- :: [Pre-Print Servers](#)
- :: [Think Tanks](#)
- :: [Public Consultations/Call for Inputs/Call for Papers](#)

Milestones, Perspectives

.....
.....

Global childhood vaccination holds steady, yet over 14 million infants remain unvaccinated – WHO, UNICEF

GENEVA/NEW YORK, 15 July 2025 –

In 2024, 89 per cent of infants globally – about 115 million – received at least one dose of the diphtheria, tetanus and pertussis (DTP)-containing vaccine, and 85 per cent – roughly 109 million – completed all three doses, according to new national immunization coverage data released today by the World Health Organization (WHO) and UNICEF.

Compared to 2023, around 171,000 more children received at least one vaccine, and one million more completed the full three-dose DTP series. While the gains are modest, they signal continued progress by countries working to protect children, even amid growing challenges.

Still, nearly 20 million infants missed at least one dose of DTP-containing vaccine last year. This includes 14.3 million “zero-dose” children who never received a single dose of any vaccine – 4 million more than the 2024 target needed to stay on track with Immunization Agenda 2030 goals, and 1.4 million more than in 2019, the baseline year for measuring progress.

"Vaccines save lives, allowing individuals, families, communities, economies and nations to flourish," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "It's encouraging to see a continued increase in the number of children being vaccinated, although we still have a lot of work to do. Drastic cuts in aid, coupled with misinformation about the safety of vaccines, threaten to unwind decades of progress. WHO remains committed to working with our partners to support countries to develop local solutions and increase domestic investment to reach all children with the lifesaving power of vaccines." ...

Access to vaccines remains deeply unequal

Since 2019, data from 195 countries show that 131 countries have consistently reached at least 90 per cent of children with the first dose of DTP, but there has been no significant movement in expanding this group. Among the countries that reached less than 90 per cent in 2019, only 17 managed to increase their coverage rates in the past five years. Meanwhile, in 47 countries, progress is stalling or worsening. This includes 22 countries that achieved and surpassed the 90 per cent target in 2019 but have since declined.

The data shows conflict and humanitarian crises can quickly erode vaccination progress. A quarter of the world's infants live in just 26 countries affected by fragility, conflict, or humanitarian crises, yet they make up half of all unvaccinated children globally.

Concerningly, in half of these countries, the number of unvaccinated children has expanded rapidly from 3.6 million in 2019 to 5.4 million in 2024, underscoring the need for humanitarian responses to include immunization.

Immunization coverage in the 57 low-income countries supported by Gavi, the Vaccine Alliance have improved in the past year, with a reduction of roughly 600,000 un- and under-vaccinated children. While Gavi-supported countries are protecting more children against more diseases than ever before, **significant challenges persist due to conflicts and population growth**. At the same time, signs of slippage are emerging in upper-middle- and high-income countries that have previously maintained at least 90 per cent coverage. Even small declines in immunization coverage can dramatically raise the risk of disease outbreaks and place additional strain on already overstretched health systems.

"The good news is that we have managed to reach more children with life-saving vaccines. But millions of children remain without protection against preventable diseases, and that should worry us all," said **UNICEF Executive Director Catherine Russell**. **"We must act now with determination to overcome barriers like shrinking health budgets, fragile health systems along with misinformation and access constraints because of conflicts. No child should die from a disease we know how to prevent."**

Broadening protection against vaccine-preventable diseases

Despite these challenges, countries – especially those supported by Gavi – continue to introduce and scale up vaccines, including against human papillomavirus (HPV), meningitis, pneumococcal disease, polio, and rotavirus...

Coverage against measles also improved, with 84 per cent of children receiving the first dose and 76 per cent receiving the second, up slightly from the previous year. An estimated 2 million more children were reached in 2024, but this coverage is far from the 95 per cent needed in every community to prevent outbreaks.

More than 30 million children remain under-protected. As a result, the number of countries experiencing large and disruptive outbreaks is expanding. **In 2024, the number of countries experiencing large or disruptive measles outbreaks rose sharply to 60, nearly doubling from 33 in 2022.**

The promise of protecting every child is at risk

Although the community demand for childhood vaccination remains high and protection against more diseases is expanding, the latest estimates highlight a concerning trajectory. National and global funding shortfalls, growing instability worldwide, and rising vaccine misinformation threaten to further stall or even reverse progress which would risk increases in severe disease and deaths from vaccine-preventable diseases.

WHO and UNICEF call on governments and relevant partners to:

- **Close the funding gap for Gavi's next strategic cycle (2026–2030)** to protect millions of children in lower-income countries and global health security;
- **Strengthen immunization in conflict and fragile settings** to reach more zero-dose children and prevent deadly disease outbreaks;
- **Prioritize local-led strategies and domestic investment**, embedding immunization firmly within primary healthcare systems to close equity gaps;
- **Counter misinformation and** further increase vaccine uptake through evidence-based approaches;
- **Invest in stronger data and disease surveillance systems** to guide high-impact immunization programmes.

.....
.....

[2024 global immunisation coverage estimates: understanding the picture in lower-income countries](#)

Gavi News Release, Geneva, 15 July 2025 –

Each year WHO and UNICEF release global and national routine immunisation coverage estimates (WUENIC). Gavi, the Vaccine Alliance analyses what the 2024 WUENIC data says

about the state of immunisation in the 57 low- and lower-middle income countries it supports.

[Text bolding from original]

KEY TAKEAWAYS

Lower-income countries are protecting more people, against more diseases than ever before in history – and coverage rates are steadily on the rise following declines during the COVID-19 pandemic.

- With Gavi routine immunisation support, lower-income countries protected **more than 72 million** children against a range of infectious diseases in 2024, more than any previous year on record. They are more committed to financing immunisation than ever before – contributing record amounts to co-finance vaccine programmes – **US\$ 255 million** in 2024 alone.
- This means Gavi's target to protect 1.1 billion children by 2025 has been surpassed – with **1.2 billion** children protected in lower-income countries since 2000.
- In 2024, coverage rates improved across all the vaccines Gavi supports, by **eight percentage points** on average, with large gains in routine coverage with vaccines against polio, cervical cancer, measles, pneumonia, rotavirus and yellow fever.
- In 2024, **70%** of lower-income countries maintained or improved coverage with three doses of the diphtheria, tetanus and pertussis-containing vaccine (DTP3) – which is often used as a proxy to measure a country's ability to consistently reach children with essential vaccinations.
- Thanks to these efforts, DTP3 coverage increased one percentage point in 2024 in lower-income countries, to **82%**. This is still one percentage point below pre-pandemic levels (2019).
- The number of zero-dose children who are yet to receive a single vaccine went down by **500,000**.

However, population growth, fragility and conflict still present major barriers to achieving true equity, leaving millions of the most vulnerable – and the world – at risk.

- Thanks to population growth, countries are having to reach more children each year to maintain coverage levels. In 2024, there were **2.5 million** (3%) more births in 2024 as compared to 2019 in the 57 lower-income countries Gavi supports.
- Despite a decline of half a million, there are still **10.2 million** zero-dose children in lower-income countries.
- DTP3 coverage rates in the 12 countries Gavi classifies as experiencing fragility and conflict held steady at **61%**, following a major decline from 68% in 2022 to 61% in 2023, with large declines in Sudan (down 12 percentage points) and Yemen (down 4 percentage points counteracting significant improvements across other fragile and conflict-impacted countries in 2024 – including large **6–7 percentage point** gains in countries such as Mali, Syria and Haiti).

Targeted efforts to reach missed children are yielding improvements, but face challenges.

- Coverage with the first dose of the DTP vaccine, or DTP1, is an important measure that helps the world understand how many zero-dose children still don't have access to life-saving vaccines. DTP1 coverage stood at **87%** in 2024 – nearly recovered from a four percentage point decrease during the COVID-19 pandemic.
- This means there are **half a million** fewer zero-dose children in lower-income countries in 2024, thanks mainly to targeted efforts in populous countries like India, DR Congo and Ethiopia.
- However, this means millions of children are still at risk. Nearly **half (4.9 million)** of all the 10.2 million zero-dose children in lower-income countries live in five populous countries – Nigeria, DR Congo, India, Pakistan and Ethiopia. These countries also account for nearly 60% of the birth cohort in Gavi-supported countries.
- Another nearly **30% (2.9 million)** of zero-dose children in lower-income countries live in fragile and conflict-affected settings.
- Gavi works closely with these countries on targeted work to reach missed children and communities, and with new partners that can help reach communities in fragile settings. For

example, Gavi's innovative Zero-dose Immunisation Programme (ZIP), implemented in partnership with NGOs and humanitarian actors, has administered 9 million vaccine doses in conflict-impacted regions in Africa, leading to an estimated **1 million** previously missed children who are now fully immunised.

- However, progress is still far behind Gavi's target of achieving a **25%** reduction in the number of zero-dose children (to 6.9 million) by 2025. Achieving this goal will require a **32%** reduction compared to 2024 figures. The COVID-19 pandemic, rising birth cohort and fragility have all played factors in slowing down progress.

Africa has now recovered immunisation coverage to pre-pandemic levels, even with an increasing birth cohort.

- The majority of the countries that Gavi supports are in Africa, a region where DTP3 coverage has fully recovered to pre-pandemic levels despite an increasing population requiring countries to reach more and more children to achieve gains.
- The WHO AFRO region saw declines in DTP3 from 76% in 2019 to 72% in 2022, but has now fully recovered in 2024 – with DTP3 coverage back up to **76%**.
- The largest gains in DTP3 in 2024 in the African region were in Mali (+7pp), DR Congo (+5pp), Rwanda (+4pp) and Ethiopia (+3pp).

Immunisation rates in Eastern-Mediterranean region drop due to conflict in Sudan and Yemen despite strong gains in other countries.

- DTP3 coverage in the Eastern-Mediterranean region dropped to **79%** due to large conflict-related declines in Sudan and Yemen, and despite gains in many Gavi-supported countries including Pakistan, Syria and Somalia.

Lower-middle income countries have recovered immunisation coverage to pre-pandemic levels, while low-income countries continue to be impacted – underscoring the importance of building resilient health systems.

- Within the 57 countries Gavi supports, lower-middle income countries have fully recovered DTP3 to pre-pandemic levels.
 - However, 26 low-income countries are still at **70%** DTP3 coverage in 2024 relative to 75% in 2019.

More girls are being protected against cervical cancer than ever before in history, with efforts well on track to achieve ambitious targets.

- At the end of 2022, Gavi revitalised its efforts to protect girls with the HPV vaccine, which protects against cervical cancer – one of the leading killers of women and girls in lower-income countries.
 - Thanks to these efforts, **more girls in lower-income countries have been protected with the HPV vaccine in 2024 than the previous decade combined.**
 - HPV vaccine coverage in lower-income countries has risen from 3% in 2019 to 7% in 2022, doubling to 16% in 2023, before increasing again to **25%** in 2024.
 - More than twice as many girls were vaccinated with Gavi support in 2024 (32.6 million) than in 2023.
 - As of 2024, **nearly 60 million** girls have been fully immunised with HPV vaccine with Gavi support, well on track towards the target of reaching 86 million girls by the end of 2025.

Immunisation rates against measles continue to improve after pandemic-related declines, but are still well below levels needed to prevent outbreaks.

- Measles immunity gaps are a significant concern, given the high transmissibility of the virus and risk for serious outbreaks.
- Measles coverage rates fell during the pandemic, with many countries delayed in carrying out planned introductions and large-scale preventive vaccination campaigns.

- For the past few years, Gavi and countries have accelerated measles efforts – reaching **hundreds of millions** of children through routine, preventive and outbreak vaccination. These efforts have translated into rising measles vaccination rates and increasing protection.
- Coverage with the first dose of measles vaccine (MCV1) was at 81% in 2019, dropping down to 77% in 2021 before reaching 78% in 2023. In 2024, MCV1 coverage increased again, by two percentage points to **80%**. This gain is largely driven by improvements in coverage in highly populous countries.
- Coverage with the second dose of measles vaccine (MCV2) has seen significant gains, with persistent efforts to introduce this vaccine into routine immunisation yielding results – starting at just 59% in 2019 and climbing steadily to **70%** in 2024.
- However, coverage remains well below the 95% threshold considered necessary to prevent outbreaks. In 2024, **15.5 million** children in lower income countries were missing the first dose of measles vaccine, accounting for **75%** of the 20.6 million global total.

.....

The Lancet

Jul 19, 2025 Volume 406 Number 10500 p203-306

Article

[Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023](#)

GBD 2023 Vaccine Coverage Collaborators

Summary

Background

Since its inception in 1974, the Essential Programme on Immunization (EPI) has achieved remarkable success, averting the deaths of an estimated 154 million children worldwide through routine childhood vaccination. However, more recent decades have seen persistent coverage inequities and stagnating progress, which have been further amplified by the COVID-19 pandemic. In 2019, WHO set ambitious goals for improving vaccine coverage globally through the Immunization Agenda 2030 (IA2030). Now halfway through the decade, understanding past and recent coverage trends can help inform and reorient strategies for approaching these aims in the next 5 years.

Methods

Based on the Global Burden of Diseases, Injuries, and Risk Factors Study 2023, this study provides updated global, regional, and national estimates of routine childhood vaccine coverage from 1980 to 2023 for 204 countries and territories for 11 vaccine-dose combinations recommended by WHO for all children globally. Employing advanced modelling techniques, this analysis accounts for data biases and heterogeneity and integrates new methodologies to model vaccine scale-up and COVID-19 pandemic-related disruptions. To contextualise historic coverage trends and gains still needed to achieve the IA2030 coverage targets, we supplement these results with several secondary analyses: (1) we assess the effect of the COVID-19 pandemic on vaccine coverage; (2) we forecast coverage of select life-course vaccines up to 2030; and (3) we analyse progress needed to reduce the number of zero-dose children by half between 2023 and 2030.

Findings

Overall, global coverage for the original EPI vaccines against diphtheria, tetanus, and pertussis (first dose [DTP1] and third dose [DTP3]), measles (MCV1), polio (Pol3), and tuberculosis (BCG) nearly doubled from 1980 to 2023. However, this long-term trend masks recent challenges. **Coverage gains slowed between 2010 and 2019 in many countries and territories, including declines in 21 of 36 high-income countries and territories for at least one of these vaccine doses**

(excluding BCG, which has been removed from routine immunisation schedules in some countries and territories).

The COVID-19 pandemic exacerbated these challenges, with global rates for these vaccines declining sharply since 2020, and still not returning to pre-COVID-19 pandemic levels as of 2023. Coverage for newer vaccines developed and introduced in more recent years, such as immunisations against pneumococcal disease (PCV3) and rotavirus (complete series; RotaC) and a second dose of the measles vaccine (MCV2), saw continued increases globally during the COVID-19 pandemic due to ongoing introductions and scale-ups, but at slower rates than expected in the absence of the pandemic. Forecasts to 2030 for DTP3, PCV3, and MCV2 suggest that only DTP3 would reach the IA2030 target of 90% global coverage, and only under an optimistic scenario. The number of zero-dose children, proxied as children younger than 1 year who do not receive DTP1, decreased by 74·9% (95% uncertainty interval 72·1–77·3) globally between 1980 and 2019, with most of those declines reached during the 1980s and the 2000s.

After 2019, counts of zero-dose children rose to a COVID 19-era peak of 18·6 million (17·6–20·0) in 2021. Most zero-dose children remain concentrated in conflict-affected regions and those with various constraints on resources available to put towards vaccination services, particularly sub-Saharan Africa. As of 2023, more than 50% of the 15·7 million (14·6–17·0) global zero-dose children resided in just eight countries (Nigeria, India, Democratic Republic of the Congo, Ethiopia, Somalia, Sudan, Indonesia, and Brazil), emphasising persistent inequities.

Interpretation

Our estimates of current vaccine coverage and forecasts to 2030 suggest that achieving IA2030 targets, such as halving zero-dose children compared with 2019 levels and reaching 90% global coverage for life-course vaccines DTP3, PCV3, and MCV2, **will require accelerated progress.** Substantial increases in coverage are necessary in many countries and territories, with those in sub-Saharan Africa and south Asia facing the greatest challenges. Recent declines will need to be reversed to restore previous coverage levels in Latin America and the Caribbean, especially for DTP1, DTP3, and Pol3. **These findings underscore the crucial need for targeted, equitable immunisation strategies.** Strengthening primary health-care systems, addressing vaccine misinformation and hesitancy, and adapting to local contexts are essential to advancing coverage. **COVID-19 pandemic recovery efforts, such as WHO's Big Catch-Up, as well as efforts to bolster routine services must prioritise reaching marginalised populations and target subnational geographies to regain lost ground and achieve global immunisation goals.**

Funding

The Bill & Melinda Gates Foundation and Gavi, the Vaccine Alliance.

.....
.....

Gavi

[How Gavi 6.0 Can Take a Bigger Leap](#)

BRIEF

Center for Global Development, July 18, 2025

Janeen Madan Keller et al.

This brief is the second in CGD's Tough Times, Tough Choices series, which offers guidance to major global health and development institutions and their funders on how to allocate resources strategically and effectively in an era of aid austerity.

Gavi's board and leadership must stretch scarce resources to fulfill a challenging double mandate: (1) stabilizing immunization outcomes and fiscal solvency in Gavi-eligible countries facing severe health

financing shocks; and (2) laying the groundwork for a durable transformation via a radically simplified “New Compact Envelope Financing” policy...


Key recommendations

Gavi 6.0 should prioritize a dual mandate:

- **Stabilize core vaccine budgets in the poorest countries**
- **Transform the financing model over time** through a radically simplified “New Compact Envelope Financing” approach, with country-led prioritization, domestic financing of top priority vaccines, and a single Gavi cash envelope to cover additional vaccines and technical assistance

Gavi can generate cost savings of ~\$2.5 billion without compromising its core mandate by:

1. Cutting direct funding to non-Gavi-eligible middle-income countries, and offering alternative forms of high-leverage support
2. Scaling back Secretariat expenses
3. Securing vaccine price reductions
4. Reducing funding for the African Vaccine Manufacturing Accelerator
5. Decreasing overall country allocations with an incremental rollout by eligibility phase



Conclusion

As Gavi operationalizes its next strategy, it must focus on achieving a critical dual mandate: (1) stabilizing and protecting the poorest countries from further immediate financing or delivery disruption; and (2) transforming its financing model via a radically simplified “New Compact Envelope Financing” approach aligned with core principles of the “Gavi Leap.”















We have proposed a viable and feasible path to do exactly that—all while saving the \$2.5 billion needed for budget solvency. We urge the Board and Secretariat to align behind this clear vision for a bigger leap into Gavi’s future—one that meets the moment of our current crisis while also laying the foundation for real sustainability.

Thanks to Rosie Eldridge for research support, and to Adrian Gheorghe and Charles Kenny for feedback and suggestions on an earlier draft.

We invite interested individuals to propose a 300-word response article with clear counter proposals, which we plan to publish as a collection later in the year.

Figure 1. Gavi pledges by top historical donors in 5.0 (2021–2025) vs. 6.0 (2026–2030)

Gavi Pledges by Top Historical Donors in 5.0 (2021–2025) vs 6.0 (2026–2030)

	Donor	Gavi 5.0 Pledge (excluding COVAX) (USD millions)	Gavi 6.0 Pledge (USD millions)	Percent Change from 5.0 to 6.0
1	 United Kingdom	2,073	1,700	-18%
2	Gates Foundation	1,577	1,600	1%
3	 Norway*	1,049	792	-24%
4	 United States**	1,170	0	-100%
5	 France	774	580	-25%
6	 Germany	716	696	-3%
7	 Canada	380	492	29%
8	 Italy	242	290	20%
9	 Australia	266	251	-6%
10	 Netherlands	242	N/A	N/A
11	 European Commission (EC)	330	302	-9%
12	 Sweden	185	N/A	N/A
13	 Spain	77	151	96%
14	 Japan	100	N/A	N/A
15	 Ireland	20	25	25%

Notes: The Netherlands, Sweden, and Japan have not yet pledged to Gavi 6.0; Gavi 5.0 pledges use Annual Contributions and Proceeds data from December 2024, excluding COVAX AMC (<https://www.gavi.org/investing-gavi/funding/donor-profiles/annual-contributions-and-proceeds>); Gavi 6.0 pledges are converted to USD using FX rates from 6/25/25 (date of pledging summit); *Norway pledged NOK 10.05 billion to Gavi 5.0 (<https://www.gavi.org/investing-gavi/funding/donor-profiles/norway>), NOK 6 billion of which was direct contributions and NOK 4 billion of which was IFFIm payments. In Gavi 6.0, Norway pledged NOK 8 billion, which includes NOK 5 billion in direct contributions and NOK 3 billion in outstanding IFFIm payments originally committed during Gavi 5.0 but scheduled for disbursement over 10 years. Because NOK 3 billion in IFFIm payments span both the Gavi 5.0 and Gavi 6.0 cycles, they are effectively counted in both, inflating the apparent value of Norway's new pledge; **The US pledged \$1.17 billion in Gavi 5.0, and the Biden Administration pledged \$1.58 billion for Gavi 6.0, but the Trump Administration has since announced that it will zero out US contributions for Gavi 6.0.

[Get the data](#) • [Download image](#) • Created with [Datawrapper](#)

.....
.....
.....

U.S. Immunization and Public Health Governance/Policy/Funding
Given the continuing extraordinary situation in the U.S., we are establishing a separate section of the digest to capture and organize key content.

.....

IHR – Amendments

[HHS & State Department: The United States Rejects Amendments to International Health Regulations](#)

HHS Media Release

WASHINGTON—JULY 18, 2025—U.S. Health and Human Services Secretary Robert F. Kennedy, Jr. and Secretary of State Marco Rubio today issued a **Joint Statement of formal rejection by the United States of the 2024 International Health Regulations (IHR) Amendments** by the World Health Organization (WHO).

The amended IHR would give the WHO the ability to order global lockdowns, travel restrictions, or any other measures it sees fit to respond to nebulous “potential public health risks.” **These regulations are set to become binding if not rejected by July 19, 2025, regardless of the United States’ withdrawal from the WHO.**

“The proposed amendments to the International Health Regulations open the door to the kind of narrative management, propaganda, and censorship that we saw during the COVID pandemic,” Secretary Kennedy said. **“The United States can cooperate with other nations without jeopardizing our civil liberties, without undermining our Constitution, and without ceding away America’s treasured sovereignty.”**

Secretary Kennedy also released a [video](#) explaining the action to the American people.

“Terminology throughout the amendments to the 2024 International Health Regulations is vague and broad, risking WHO-coordinated international responses that focus on political issues like solidarity, rather than rapid and effective actions,” Secretary Rubio said. “Our Agencies have been and will continue to be clear: we will put Americans first in all our actions and we will not tolerate international policies that infringe on Americans’ speech, privacy, or personal liberties.”...

Praise for today’s action from members of Congress [Quotes from Senator Ron Johnson, Congressman Tom Tiffany, Congressman Chip Roy Congressman Andy Biggs.

Today’s announcement is the latest action by Secretary Kennedy and HHS to [hold the WHO accountable.](#)

.....

[Joint Statement by Secretary of Health and Human Services Robert F. Kennedy, Jr. and Secretary of State Marco Rubio on International Health Regulations Amendments](#)

United States Rejection of 2024 Amendments to the International Health Regulations (2005)
Jul 18, 2025, HHS Joint Statement

“Today, the Department of State, in collaboration with the Department of Health and Human Services (HHS), transmitted the official U.S. rejection of the 2024 amendments to the International Health Regulations (IHR) (2005). This action delivers on our promise to the American people – to fight for Americans in the international system, protect our national sovereignty, and prevent international bureaucrats from shaping U.S. domestic policies.

“In 2024, the World Health Assembly (WHA) adopted amendments to the International Health Regulations (IHR) that significantly expanded the World Health Organization’s (WHO) authority over

international public health responses. Developed without adequate public input, these amendments expand the role of the WHO in public health emergencies, create additional authorities for the WHO for shaping pandemic declarations, and promote WHO's ability to facilitate "equitable access" of health commodities. These amendments have undue influence on our domestic health responses from WHO directives. They also fail to adequately address the WHO's susceptibility to the political influence and censorship - most notably from China - during outbreaks. These amendments were set to become binding on the United States regardless of our withdrawal from the WHO.

"Terminology throughout the 2024 amendments is vague and broad, risking WHO-coordinated international responses that focus on political issues like solidarity, rather than rapid and effective actions. The amendments also suggest that countries develop capabilities that jeopardize management and dissemination controls over public health information, potentially stifling valuable scientific debate. Furthermore, these revisions compel countries to adopt digital health documents.

"Our Agencies have been and will continue to be clear: we will put Americans first in all our actions and we will not tolerate international policies that infringe on Americans' speech, privacy, or personal liberties. These amendments risk unwarranted interference with our national sovereign right to make health policy. We are proud to have worked jointly to ensure public health policy continues to be dictated by the values and will of the American people, not unelected global actors."

.....
.....

White House, HHS, FDA, CDC+

White House

Presidential Actions – Executive Orders; Memoranda; Proclamations
No new digest content identified.

HHS

News

[HHS & State Department: The United States Rejects Amendments to International Health Regulations](#)

July 18, 2025 Press Release

[Joint Statement by Secretary of Health and Human Services Robert F. Kennedy, Jr. and Secretary of State Marco Rubio on International Health Regulations Amendments](#)

July 18, 2025 Press Release

NIH [to 19 July 2025]

<http://www.nih.gov/>

News Releases

No new digest content identified

FDA

Press Announcements

No new digest content identified

CDC/ACIP [to 19 July 2025]

<http://www.cdc.gov/media/index.html>

Latest News

No new digest content identified.

ACIP Meetings [to 19 July 2025]

Next ACIP Meetings

:: August/September (dates TBD)

:: October 22-23

MMWR Weekly

<https://www.cdc.gov/mmwr/index2025.html>

No new digest content identified.

FDA VRBPAC

Advisory Committee Calendar

Advisory Committee Calendar has no meetings posed for any Advisory Committee

FDA Pediatric Advisory Committee Meeting

Advisory Committee Calendar has no meetings posed for any Advisory Committee

National Vaccine Program

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No 2025 meeting dates posted.

Advisory Commission on Childhood Vaccines (ACCV)

<https://www.hrsa.gov/advisory-committees/vaccines/meetings>

Next ACCV Meeting - TBD

.....
.....

U.S. Congress

House of Representatives

H.R.4 - Rescissions Act of 2025 [text]

Legislative action of 18 July rescinding already legislated and committed funds, including funding for numerous international organizations [analysis continuing]

U.S. Senate

Voices of the Vaccine Injured – *Hearing: Recording/Testimony*

Senate Committee on Homeland Security & Governmental Affairs | Permanent Subcommittee on Investigations

July 15, 2025

.....
.....

U.S. Policy Tracking – Kaiser Family Foundation

No new digest content identified.

.....
.....
.....

Polio – PHEIC

Polio this week – 16 July 2025

Headlines [Selected]

:: IMB convening in Geneva

The Independent Monitoring Board (IMB) and Transition Independent Monitoring Board (TIMB) of the Global Polio Eradication Initiative (GPEI) are convening this week in Geneva, Switzerland. Together with GPEI partners and government representatives of key countries, including Pakistan, Afghanistan, Nigeria and DR Congo, the current status of polio eradication will be reviewed and analysed. The IMB

:: Inspiring video of polio health workers in action

Dr Hamid Jafari, Director for Polio Eradication in WHO's Eastern Mediterranean Region, shares an inspiring and moving video of polio health workers going to great lengths to reach every single last child. "We must do all we can to support their endeavors to end polio." [More](#).

Summary of new polioviruses this week, cases and positive environmental isolates:

- Pakistan: 41 WPV1-positive environmental samples
- Chad: one cVDPV2 case
- Nigeria: one cVDPV2 case
- Papua New Guinea: six cVDPV2-positive environmental samples
- Sudan: one cVDPV2-positive environmental sample
- Yemen: seven cVDPV2 cases

.....
.....

mPox – PHEIC

No new digest content identified.

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

WHO & Regional Offices [to 19 July 2025]

<https://www.who.int/news>

Selected News/Announcements/Statements

5 July 2025 *News release*

[Senegal joins growing list of countries that have eliminated trachoma](#)

15 July 2025 *Joint News Release*

[Global childhood vaccination coverage holds steady, yet over 14 million infants remain unvaccinated – WHO, UNICEF](#)

14 July 2025 *News release*

[WHO recommends injectable lenacapavir for HIV prevention](#)

Major new policy updates announced at the IAS 2025 conference

14 July 2025 News release Geneva

The World Health Organization (WHO) released today new guidelines recommending the use of injectable lenacapavir (LEN) twice a year as an additional pre-exposure prophylaxis (PrEP) option for HIV prevention, in a landmark policy action that could help reshape the global HIV response. The guidelines are being issued at the 13th International AIDS Society Conference (IAS 2025) on HIV Science, in Kigali, Rwanda.

LEN, the first twice-yearly injectable PrEP product, offers a highly effective, long-acting alternative to daily oral pills and other shorter-acting options. With just two doses per year, LEN is a transformative step forward in protecting people at risk of HIV – particularly those who face challenges with daily adherence, stigma, or access to health care.

"While an HIV vaccine remains elusive, lenacapavir is the next best thing: a long-acting antiretroviral shown in trials to prevent almost all HIV infections among those at risk," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "The launch of WHO's new guidelines, alongside the FDA's recent approval, marks a critical step forward in expanding access to this powerful tool. WHO is committed to working with countries and partners to ensure this innovation reaches communities as quickly and safely as possible."

The new guidelines come at a critical moment as HIV prevention efforts stagnate with 1.3 million new HIV infections occurring in 2024 – with disproportionate impact among key and priority populations, including sex workers, men who have sex with men, transgender people, people who inject drugs, people in prisons, and children and adolescents. WHO's recommendation on LEN signals a decisive move to expand and diversify HIV prevention, giving people more options to take control over their health with choices that fit their lives.

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

Web pages not responding at inquiry.

WHO Region of the Americas PAHO

:: 15 Jul 2025

Immunization in the Americas shows progress, but over 1.4 million children missed routine vaccines in 2024

PAHO urges countries to intensify efforts to reach unvaccinated children and close gaps in access to vaccines

Washington, D.C., 15 July 2025 (PAHO)– Childhood immunization in the Americas has shown encouraging signs of recovery in 2024, but significant gaps remain. According to new data released today by the World Health Organization (WHO) and...

WHO South-East Asia Region SEARO

:: 15 July 2025 News release

South Asia immunizes a record-high number of children in 2024

WHO European Region EURO

No new digest content identified.

WHO Eastern Mediterranean Region EMRO

:: 15 July 2025

Childhood vaccination rates lag in Europe – fueling further resurgence of measles and whooping cough

Joint News Release

Vaccine complacency across Europe and Central Asia is threatening child health, reveals new data from UNICEF and WHO

WHO Western Pacific Region

:: 17 July 2025 Media release

[HPV vaccine rollout begins: A life-saving shot for the girls of Solomon Islands](#)

.....

WHO - Emergency situation reports

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

[Public Health Situation Analysis - Upper Nile State, South Sudan](#)

[Public Health Situation Analysis - occupied Palestinian territory](#)

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

No new digest content identified.

.....

Weekly Epidemiological Record

Vol. 100, Nos. 29/30, pp. 285–302 18 July 2025

<https://www.who.int/publications/journals/weekly-epidemiological-record>

:: WHO Alliance for the Global Elimination of Trachoma: progress report on elimination of trachoma, 2024–2025

.....

New WHO Publications

<https://www.who.int/publications>

Selected

18 July 2025

[WHO Alliance for the Global Elimination of Trachoma: progress report on elimination of trachoma, 2024–2025](#)

17 July 2025

[Interim medical countermeasures network: report of the second annual partners meeting, Geneva, Switzerland,...](#)

17 July 2025

[Climate change, air pollution, pollen and health](#)

16 July 2025

[Risk communication and community engagement readiness and response toolkit: ebola disease](#)

16 July 2025

[Policy considerations for strengthening preparedness and response to arbovirus epidemics and pandemics](#)

14 July 2025

[Overview of WHO recommendations on HIV and sexually transmitted infection testing, prevention, treatment,...](#)

14 July 2025

[Recommendations on the delivery of health services for the prevention and care of sexually transmitted...](#)

14 July 2025

[Country guidance for planning triple elimination of mother-to-child transmission of HIV, syphilis and...](#)

14 July 2025

[Integrating HIV, viral hepatitis and sexually transmitted infections with primary health care – Learning...](#)

14 July 2025

[Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure...](#)

.....

.....

Europe

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

Surveillance and monitoring

[Communicable disease threats report, 12-18 July 2025, week 29](#)

18 Jul 2025

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 12-18 July 2025 and includes updates on dengue, chikungunya virus disease, Crimean-Congo haemorrhagic fever, West Nile virus infection, respiratory virus epidemiology in the EU/EEA, Influenza A(H5N1), mpox, Nipah virus disease and mass gathering monitoring of UEFA Women's EURO 2025 in Switzerland.

Surveillance and monitoring

[Seasonal surveillance of dengue in the EU/EEA, weekly report](#)

18 Jul 2025

This report gives an overview of the countries and areas where dengue cases – and their corresponding case numbers - have been reported to the European surveillance portal for infectious diseases (EpiPulse).

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

No new digest content identified.

.....
.....

Africa CDC [to 19 July 2025]

<https://africacdc.org/>

Press Releases, Statements [Selected]

Press Releases

[Africa Launches Continental Strategy to Decentralize Diagnostics and Accelerate Outbreak Response](#)

Africa CDC convened public health leaders from ten African countries in Yaoundé to co-develop a continental framework for decentralizing laboratory services.

18 July 2025

.....

China CDC+

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 19 July 2025]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

National Medical Products Administration – PRC [to 19 July 2025]

<http://english.nmpa.gov.cn/>

News

No new digest content identified.

China CDC

CCDC Weekly Reports: Current Volume (7)

2025-07-18 / No. 29

[PDF of this issue](#)

- Vital Surveillances: Notified Vector-Borne Diseases — China, 2005–2024
- Vital Surveillances: A Comprehensive Analysis and Forecast of Rabies Epidemic and Elimination Challenges — China, 2005–2023
- Methods and Applications: Mapping the Global Antigenic Evolution of Human Influenza A/H3N2 Neuraminidase Based on a Machine Learning Model — 1968–2024
- Review: Clade Ib Mpox Virus: How Can We Respond?

.....
.....

[Contents \[click to move among sections\]](#)

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Organization Announcements

Paul G. Allen Frontiers Group [to 19 July 2025]

<https://alleninstitute.org/news-press/>

Recent News

[Mapping the brain to improve lives](#)

Jul 17, 2025

A collaborative effort between UW and the Allen Institute is creating a first-of-its-kind brain atlas, paving the way for breakthroughs in

News

[Allen Institute names Sarah Norris Hall as next Chief Financial Officer](#)

Jul 14, 2025

Norris Hall's experience and insight into financial operations will help enable and propel transformative science at the Allen Institute.

BMGF - Gates Foundation [to 19 July 2025]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases & Statements

[National Philanthropies Join Forces to Advance Economic Mobility and Access to Opportunity in America](#)

NextLadder Ventures launches with over \$1 billion to empower low-income Americans through personalized, tech-driven solutions

July 17, 2025

CARB-X [to 19 July 2025]

<https://carb-x.org/>

News

No new digest content identified.

Chan Zuckerberg Initiative [to 19 July 2025]

<https://chanzuckerberg.com/newsroom/>

Newsroom

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 19 July 2025]

<http://cepi.net/>

CEPI News, Blog

Impact story

[Getting ahead of pandemic threats with better, faster, AI vaccine design](#)

H5N1 doesn't have the mutations needed to spread easily between people. Yet. If it does, the global response time will be critical. Find out how new AI techniques are boosting the speed and success of
17 Jul 2025

CIDRAP – Vaccine Inventory Project

<https://www.cidrap.umn.edu/vaccine-integrity-project>

News, Viewpoints

No new digest content identified.

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 19 July 2025]

<https://cioms.ch/>

News; Publications; Events

[CIOMS cumulative glossary \(version 2.3\) now available](#)

The CIOMS cumulative glossary is an organized collection of the terms and definitions included in published CIOMS Working Group reports, with a focus on pharmacovigilance.

[CIOMS Glossary of ICH Terms & Definitions](#)

A glossary of ICH terms and definitions has been compiled by [CIOMS](#) from across ICH Guidelines. For information on this helpful CIOMS initiative, please visit the [CIOMS website](#), where the glossary is freely available for download, providing a useful resource for both CIOMS and ICH Stakeholders and Working Groups.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 19 July 2025]

<https://www.darpa.mil/news>

News

No new digest content identified.

DNDI – Drugs for Neglected Diseases initiative [to 19 July 2025]

<https://dndi.org/press/press-releases/>

Press Releases

Publications 15 Jul 2025

[DNDi 2024 Annual Report](#)

Duke Global Health Innovation Center [to 19 July 2025]

<https://dukeghic.org/>

News

No new digest content identified.

EDCTP [to 19 July 2025]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified.

Emory Vaccine Center [to 19 July 2025]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 19 July 2025]

<http://www.euvaccine.eu/>

Latest News, Events

EVI launches new global collaboration to advance promising malaria vaccine candidate: SEmalvac6

New EVI-led project aims to boost malaria control with innovative vaccine technology through international partnership and support by the Global Health Innovative Technology

Fondation Merieux [to 19 July 2025]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gates Medical Research Institute [to 19 July 2025]

<https://www.gatesmri.org/news>

The Gates Medical Research Institute is a non-profit organization dedicated to the discovery, development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited.

News: Articles and Publications

No new digest content identified.

Gavi [to 19 July 2025]

<https://www.gavi.org/>

Press Releases

15 July 2025

2024 global immunisation coverage estimates: understanding the picture in lower-income countries

GE2P2 Global Foundation [to 19 July 2025]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – May 2025](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 25 May 2025](#)

:: [Genomics :: Governance, Ethics, Policy, Practice – A Monthly Digest – May 2025](#)

GHIT Fund [to 19 July 2025]

<https://www.ghitfund.org/newsroom/press>

Press Releases

July 17, 2025

Total Investment of Approx. USD 7.3 Million in Malaria and TB R&D projects with Partners including European Vaccine Initiative, University of Copenhagen, and University of Tübingen

Global Fund [to 19 July 2025]

<https://www.theglobalfund.org/en/news/>

News Releases

09 July 2025

[Global Fund Secures Access to Breakthrough HIV Prevention Drug Lenacapavir for Low- and Middle-Income Countries](#)

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) today announced it has signed an access agreement with Gilead Sciences to procure lenacapavir, a long-acting injectable for HIV prevention, for low- and middle-income countries...

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 19 July 2025]

<https://www.glopid-r.org/>

Website not responding at inquiry.

Hilleman Laboratories [to 19 July 2025]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 19 July 2025]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [to 19 July 2025]

<https://www.humanimmunomeproject.org/>

News

No new digest content identified.

IAVI [to 19 July 2025]

<https://www.iavi.org/>

Press Releases, Features

No new digest content identified.

INSERM [to 19 July 2025]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 19 July 2025]

<https://www.ich.org/>

News/Pubs/Press Releases [Selected]

Ongoing Public Consultations		^
>	M13B EWG Bioequivalence for Immediate-Release Solid Oral Dosage Forms	
>	Q1 EWG Stability Testing of Drug Substances and Drug Products	
>	M4Q(R2) EWG Revision of M4Q(R1)	
>	E21 EWG Inclusion of Pregnant and Breastfeeding Individuals in Clinical Trials	

<https://www.ich.org/page/public-consultations>

ICRC [to 19 July 2025]

<https://www.icrc.org/en/news>

News

Syria: ICRC warns of deteriorating humanitarian conditions in Sweida and southern Syria

News release

18-07-2025

Yemen: A new medical clinic opens at Sa'ada New Remand Prison to improve health and living conditions of detainees

News release

14-07-2025

IFFIm [to 19 July 2025]

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 19 July 2025]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press releases

No new digest content identified.

IPPS - International Pandemic Preparedness Secretariat [to 19 July 2025]

<https://ippsecretariat.org/news/>

News

No new digest content identified.

Institut Pasteur [to 19 July 2025]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

ISC / International Science Council [to 19 July 2025]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

No new digest content identified.

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News/Events [Selected]

[A message from IUIS President, Dr Miriam Merad](#)

July 2, 2025

[Excerpt]

...When I joined the Executive Committee as President-Elect in late 2019, COVID-19 was just emerging. In the months that followed, immunology became central to the world's response. Decades of foundational work by IUIS scientists enabled the rapid development of life-saving vaccines. These scientific advances not only saved millions of lives but also prevented the collapse of the global economy. For a brief moment, humanity seemed to understand that our greatest threats are not other humans, but microbes, climate disasters, and existential risks such as nuclear accidents. Wars paused, global collaborations blossomed. Science stood at the center of global hope.

I believed then—and still believe now—that COVID could have marked a turning point. It could have elevated public trust in science, fostered new forms of international solidarity, and inspired a global reordering of priorities around health, equity, and knowledge.

But the opposite is unfolding. **In the United States and beyond, the very science that protected humanity is now being vilified. Vaccine science is under attack, often by individuals with no expertise, driven by misinformation and political agenda. Funding for vaccine research has been slashed and the U.S. National Institutes of Health—arguably the world's most productive engine of biomedical discovery—is now at risk of unprecedented budget cuts**

This is not simply a U.S. issue. It is a global crisis. That's why we must act—with urgency and clarity—to reclaim the narrative and remind the public what science makes possible.

Today, I call on each of you—immunologists, trainees, colleagues, allies—to speak up. Use your voice. Share your knowledge, your stories, your impact. I welcome your ideas and contributions, including reflections and posts we can feature on the IUIS website to amplify our voice.

It is time for scientists to step beyond the lab and explain to the public what we do, how we think, and how our work leads to new cures. We must take the time to explain—clearly and humbly—why science is not a luxury, but the foundation of human progress, global health, and economic prosperity.

Let's rise together—to reclaim the narrative on science and reaffirm its role in shaping a healthier and more prosperous world.

With solidarity, urgency, and hope, Miriam Merad, IUIS President

IVAC [to 19 July 2025]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

U.S. Measles Tracker

[Tracking Measles Cases in the U.S.](#)

Updated July 17, 2025

IVI [to 19 July 2025]

<http://www.ivi.int/>

IVI News & Announcements

No new digest content identified.

Johns Hopkins Center for Health Security [to 19 July 2025]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

No new digest content identified.

MSF/Médecins Sans Frontières [to 19 July 2025]

<http://www.msf.org/>

Latest [Selected Announcements]

Mozambique

[Access to healthcare is being compromised by violence in Cabo Delgado](#)

Press Release 16 Jul 2025

National Academy of Medicine - USA [to 19 July 2025]

<https://nam.edu/programs/>

Jul 16, 2025

[Building Trust from the Ground Up: How Community Partnerships Can Shape Health and Climate Solutions](#)

Jul 15, 2025

[On the Frontlines: How the Health Sector is Responding to a Changing Climate](#)

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 19 July 2025]

<https://www.nationalacademies.org/newsroom>

News

[National Academies Appoint Three Executive Directors for New Centers and International Office](#)

The National Academies have announced the appointment of executive directors for three of the institution's new centers and offices. Tina Bahadori will lead the Center for Advancing Science and Technology; Elizabeth Eide will lead the Center for Health, People, and Places; and Vaughan Turekian will lead the Office of International Networks, Collaboration, and Security.

Date 2025-07-16

Type News Release

[Congress and Federal Health Agencies Should Take Steps to Better Align U.S. Investment in New Disease Therapies With Americans' Unmet Medical Needs](#)

A new report calls for changes and congressional action to address the misalignment between the true burden of disease in the U.S. and areas of therapeutic development in which research funders invest.

Date 2025-07-14

Type News Release

PATH [to 19 July 2025]

<https://www.path.org/media-center/>

Newsroom [Selected]

Statement on rescissions to global health programs

July 18, 2025 by PATH

Washington, DC, USA, July 18, 2025—Today, just four months after receiving broad bipartisan approval in the fiscal year 2025 budget, Congress passed the Rescissions Act of 2025, rescinding \$500 million in global health funding.

PATH was relieved to see the Senate make important adjustments to the House-passed rescission package, rejecting a proposed \$400 million cut to the President's Emergency Plan for AIDS relief (PEPFAR), and taking steps to safeguard vital global health programs—preserving investments that combat infectious diseases like malaria and tuberculosis, improve maternal and child survival, and expand access to essential nutrition interventions.

Unfortunately, these cuts will still impact numerous other lifesaving programs and remove vital funding for global actors like the World Health Organization and the United Nations Children's Fund. The cuts will threaten decades of progress in better health for families around the world and weaken America's defenses against global health threats.

We commend the leaders in Congress who fought for the protection of these essential, lifesaving programs and who voted against the cuts. As Congress now looks ahead to next year's budget, PATH will continue to work with lawmakers in both parties to protect and advance US investments that save lives and improve access to care.

Sabin Vaccine Institute [to 19 July 2025]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified.

UNAIDS [to 19 July 2025]

<http://www.unaids.org/en>

News, Stories, Updates

Press Statement

UNAIDS welcomes new WHO guidelines on Lenacapavir

GENEVA, 15 July 2025—Lenacapavir—a long-acting, six-monthly injectable antiretroviral medicine manufactured by Gilead Sciences—is now recommended by the World Health Organization as an additional HIV prevention choice as part of combination HIV prevention approaches.

Lenacapavir, a new pre-exposure prophylaxis (PrEP) medicine, has the potential to increase the uptake of PrEP and bolster HIV prevention overall as it allows people to choose a method that they prefer. Lenacapavir, administered twice a year, is highly effective at reducing the risk of HIV acquisition.

At a time when funding cuts could lead to an additional 6 million HIV infections and 4 million AIDS-related deaths by 2029, long-acting injectable medicines are a fresh option for all people at risk for HIV—especially those who face higher risk and in locations where the virus is highly prevalent: adolescent women and girls, LGBTQI+ people, sex workers and people who use drugs.

As Gilead has not yet registered Lenacapavir for regulatory approval in all countries, many people, including those facing disproportionate risk for HIV, may have to wait longer than others to access this life-saving tool...

UNICEF [to 19 July 2025]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements [Selected]

Remarks 16 July 2025

UNICEF Executive Director Catherine Russell's remarks on the humanitarian situation for children in Gaza at the UN Security Council meeting

NEW YORK, 16 July 2025 -, "Excellencies, good afternoon. Thank you to Pakistan, as president of the Council, and to Member States for bringing us together this afternoon. Thank you for inviting UNICEF to share our firsthand perspective on this desperate situation for Gaza's 1 million children. "From the beginning ...

Press release 14 July 2025

Global childhood vaccination holds steady, yet over 14 million infants remain unvaccinated – WHO, UNICEF

GENEVA/NEW YORK, 15 July 2025 –, In 2024, 89 per cent of infants globally – about 115 million – received at least one dose of the diphtheria, tetanus and pertussis (DTP)-containing vaccine, and 85 per cent – roughly 109 million – completed all three doses, according to new national immunization coverage data relea...

Unitaid [to 19 July 2025]

<https://unitaid.org/>

News

News releases

Unitaid and partners announce new financing agreement with Synergy Gases Ltd to boost medical oxygen access in sub-Saharan Africa

15 July 2025

Vaccine Equity Cooperative [nee Initiative] [to 19 July 2025]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccine Confidence Project [to 19 July 2025]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children's Hospital of Philadelphia [to 19 July 2025]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

June/July 2025: Thimerosal in Multidose Vaccine Vials: Then and Now

Dr. Paul Offit talks about the history of thimerosal in vaccines. You'll also find resources related to COVID-19 vaccines, measles outbreaks, and the June ACIP meeting.

Wellcome Trust [to 19 July 2025]

<https://wellcome.org/news/all>

News. Opinion, Reports

No new digest content identified.

The Wistar Institute [to 19 July 2025]
<https://www.wistar.org/news/press-releases>
Press Releases
No new digest content identified.

World Bank [to 19 July 2025]
<http://www.worldbank.org/en/news/all>
All News [Selected]
No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 19 July 2025]
<https://www.wfpha.org/>
Blog, Events
No new digest content identified.

World Medical Association [WMA] [to 19 July 2025]
<https://www.wma.net/news-press/press-releases/>
Press Releases

WHPA urges WHO to maintain strong leadership on health workforce

16 July 2025—The WHPA leadership is demanding that WHO continue to provide support and investment in the health workforce despite recent funding cuts and organizational restructuring. They are deeply concerned about the shake-up at WHO which has left the Health Workforce Department severely reduced in size and subsumed under the WHO Academy, WHO's newly established learning provider.

"To effectively support and strengthen health professionals, we need leadership and reliable expertise in areas like workforce planning, retention and recruitment as well as international migration and workforce shortages. We strongly encourage WHO to continue to provide visible leadership and global expertise on health workforce issues," said Dr Otmar Kloiber, Chair of WHPA and Secretary General of the World Medical Association in a strongly worded open letter from the WHPA leadership to WHO's Director General, Dr. Tedros Adhanom Ghebreyesus.

WHPA leaders are particularly concerned about the timing of the restructuring. At least three major challenges loom over future conditions for the health workforce: a projected health workforce shortage of 11 million by 2030; the ever-present danger of the next pandemic; and increasing conflicts and disasters where health professionals often risk their lives to save others. With this letter, WHPA is advocating against WHO de-prioritizing health workforce issues and the disastrous results it would have for health professionals around the world.

World Organisation for Animal Health [OIE] [to 19 July 2025]
<https://www.oie.int/>
Press Releases, Statements
No new digest content identified.

.....
.....

ARM [Alliance for Regenerative Medicine] [to 19 July 2025]
<https://alliancerm.org/press-releases/>
Selected Press Releases

No new digest announcements identified.

BIO [to 19 July 2025]

<https://www.bio.org/press-releases>

Press Releases

No new digest announcements identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 19 July 2025]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest announcements identified.

ICBA – International Council of Biotechnology Associations [to 19 July 2025]

<https://internationalbiotech.org/news/>

News

No new digest announcements identified.

IFPMA [to 19 July 2025]

<https://ifpma.org/>

News, Statements [Selected]

No new digest announcements identified.

International Alliance of Patients' Organizations – IAPO [to 19 July 2025]

<https://www.iapo.org.uk/news>

Press and media [Selected]

No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest announcements identified.

PhRMA [to 19 July 2025]

<http://www.phrma.org/>

Press Releases

No new digest announcements identified.

.....
.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

We recognize that this listing is indicative but certainly not exhaustive. We invite nomination of other vaccine developers for potential addition to those monitored below.

AstraZeneca

Press Releases - No new digest announcements identified.

Bavarian Nordic

Latest News - No new digest announcements identified.

BioCubaFarma – Cuba

Últimas Noticias - No new digest announcements identified.

Biological E

News - No new digest announcements identified.

BioNTech

Press Releases

17 July 2025

[BioNTech Announces Ryan Richardson to Step Down from the Management Board](#)

...Ryan Richardson will step down as Chief Strategy Officer in the Management Board of BioNTech on September 30, 2025, and as a Board Director at affiliated companies of the BioNTech Group by mutual agreement to pursue new professional opportunities. The process of transitioning his responsibilities to other members of the Management Board is underway, ensuring a smooth handover...

Boehringer

Press Releases - No new digest announcements identified.

CanSinoBIO

News - Website not responding at inquiry.

CIGB

Latest News - No new digest announcements identified.

CinnaGen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals – China

News - No new digest announcements identified.

Curevac

News - No new digest announcements identified.

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media

17 July 2025

[US FDA approves GSK's Shingrix in a prefilled syringe presentation](#)

14 July 2025

[ViiV Healthcare extends voluntary licensing agreement with Medicines Patent Pool to enable access to innovative long-acting injectable HIV treatment](#)

14 July 2025

[ViiV Healthcare data show 89% of treatment-naïve people with HIV choose to switch to long-acting injectable Vocabria + Rekambys from daily pills after achieving rapid viral suppression](#)

14 July 2025

[US FDA accepts application to review expanded use of GSK's RSV vaccine, Arexvy, for adults 18-49 at increased risk](#)

EuBiologics, S Korea

News - No new digest announcements identified.

IMBCAMS, China

Home - Website not responding at inquiry.

JNJ Innovative Medicine [Janssen]

Press Releases - No new digest announcements identified.

Merck

News releases

July 14, 2025

[Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill](#)

In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally

Nanogen

News - No new digest announcements identified.

Novartis

News - No new digest announcements identified.

Novavax

Press Releases - No new digest announcements identified.

Pfizer

Recent Press Releases - No new digest announcements identified.

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

Press Releases

July 18, 2025

[Press Release: Sanofi completes acquisition of Blueprint Medicines](#)

Serum Institute

News & Announcements - No new digest announcements identified.

Sinopharm/WIBPBIBP

News - No new digest announcements identified.

Sinovac

Press Releases - No new digest announcements identified.

SK Biosciences

Press Releases

SK bioscience Receives Approval for Clinical Trials of 21-valent Pneumococcal Vaccine Candidate in China

Green light for Phase 1 and 3 trials paves the way for Chinese market entry
2025.07.18

SK bioscience Submits IND for Phase 1/2 Clinical Trial of Adjuvanted Influenza Vaccine Candidate

Company aims for technology advancement and platform expansion with Korea's first influenza vaccine
2025.07.17

Takeda

Newsroom - No new digest announcements identified.

Valneva

Press Releases - No new digest announcements identified.

Vector State Research Centre of Virology and Biotechnology

Home - [Website not responding [404 error]]

WestVac Biopharma

Media - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

.....
.....

Contents [click to move among sections]

:: Milestones, Perspectives

:: WHO

:: Organization Announcements

:: Journal Watch

:: Pre-Print Servers

.....
.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 16, 2025 Issue 2

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 27, Number 7: E479-540

<https://journalofethics.ama-assn.org/issue/embodiment-art-practice>

Rural US Emergency Medical Services

Emergency medical services (EMS) are the most immediate health care resource for many US residents living in rural areas. We all rely on EMS to coordinate deployment of networks of transporters, first-responders, basic and intermediate emergency medical technicians, paramedics, and medical directors. These clinicians bring professional skill sets and scopes of practice to their crews when our health needs are urgent. Yet, low call volume in rural areas hinders responders' exposure to real-life procedures and undermines reimbursement for services rendered, so many rural EMS programs must depend—and perhaps overly rely—on volunteers. Air transport and telehealth help some rural US residents overcome some proximity demands but are imperfect workarounds for meeting critical vulnerabilities and do not substantially mitigate rural/urban emergent care access inequity. This theme issue explores rural EMS as a source of clinical, legal, and policy-level questions neglected in health care ethics, policy, and equity discussions.

American Journal of Human Genetics

Jul 03, 2025 Volume 112 Issue 7 p1497-1732

<https://www.cell.com/ajhg/current>

This month in The Journal

Alyson B. Barnes, Sara B. Cullinan

Newborn screening (NBS) contributes to reduced newborn morbidity and mortality globally. While reducing morbidity and mortality is already a public health success, the need for expanded and more widely adopted NBS initiatives is emphasized by the United Nations' goal to end preventable deaths of newborns and children under five years old by 2030. Incorporating genomic sequencing into NBS programs would enable earlier identification of a wide range of conditions, pushing us closer to this goal. Indeed, the value of including genomic sequencing in NBS programs is well recognized in the medical community, but an important component of ensuring successful implementation of such programs is understanding public values.

American Journal of Infection Control

August 2025 Volume 53 Issue 8 p809-918

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

July 2025 Volume 69 Issue 1

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

August 2025 115(8)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 113 (2025): Issue 1 (Jul 2025)

<https://www.ajtmh.org/view/journals/tpmd/113/1/tpmd.113.issue-1.xml>

Articles

[Pneumococcal Carriage in the Sahel Region of Burkina Faso before a 13-Valent Pneumococcal Conjugate Vaccination Campaign](#)

Robert Lamoussa Zoma, et al.

Article Category: Research Article

DOI: <https://doi.org/10.4269/ajtmh.24-0746>

[Barriers and Facilitators for Participation in Global Health Research Training Programs Among Underrepresented Minority Groups](#)

Usha Ramakrishnan, et al.

Article Category: Research Article

DOI: <https://doi.org/10.4269/ajtmh.24-0847>

The Tropical Bookshelf

[A Review of Vaccines for Neglected Pathogens: Strategies, Achievements, and Challenges – Focus on Leprosy, Leishmaniasis, Melioidosis, and Tuberculosis](#) by Myron Christodoulides

Christian T. K.-H. Stadtländer

Annals of Internal Medicine

July 2025 Volume 178, Issue 7

<https://www.acpjournals.org/toc/aim/current>

[New issue; No digest content identified]

Artificial Intelligence – An International Journal

Volume 345 August 2025

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/345/suppl/C>

[New issue; No digest content identified]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 19 July 2025)

[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 19 July 2025)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 19 July 2025)

[No new digest content identified]

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 19 July 2025)

[Informed consent in genetic and genomic studies in Sub-Saharan Africa: a systematic review of bioethical issues](#)

International collaboration on genetic/genomic studies has expanded dramatically. Informed consent remains a cornerstone for protecting participant autonomy. Over the past few decades, guidelines, recommendati...

Authors: Yunqi Li, Deborah J. Bowen and Joon-Ho Yu

Citation: BMC Medical Ethics 2025 26:99

Content type: Systematic Review Published on: 19 July 2025

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 19 July 2025)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 19 July 2025)

No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 19 July 2025)

[The optimal strategy for seasonal influenza vaccination to prevent high-intensity level of influenza epidemics in Zhejiang, China: an integrated transmission-dynamic and health-economic modeling analysis](#)

Although Seasonal Influenza Vaccination (SIV) is a crucial preventive measure, achieving sufficient coverage to completely control influenza epidemics poses a significant challenge. This study aims to evaluate...

Authors: Mengsha Chen, Mengya Yang, Rui Yan, Zhengwei Liu, Can Chen, Rongrong Qu, Wenkai Zhou, Jiaxing Qi, Kexin Cao, Jiani Miao, Xiaoyue Wu, Jiaxin Chen, Qianqian Feng, HuiHui Zhang, Anqi Dai, Yi Yang...

Citation: BMC Public Health 2025 25:2459

Content type: Research Published on: 15 July 2025

[Development and psychometric evaluation of the vaccine knowledge test for childhood vaccinations: using Rasch analysis](#)

There is a clear need for an up-to-date, comprehensive, and methodologically tested tool to assess parents' knowledge of childhood immunization. The aim of this study was to develop a vaccine knowledge test fo...

Authors: Deniz Kocoglu-Tanyer and Deniz S. Yorulmaz Demir

Citation: *BMC Public Health* 2025 25:2449

Content type: Research Published on: 14 July 2025

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 19 July 2025)

[No new digest content identified]

BMJ Evidence-Based Medicine

June 2025 - Volume 30 - 3

<https://ebm.bmj.com/content/30/3>

[Reviewed earlier]

BMJ Global Health

July 2025 - Volume 10 - 7

<https://gh.bmj.com/content/10/7>

[Reviewed earlier]

Bulletin of the Atomic Scientists

DIGITAL MAGAZINE - May 2025

<https://thebulletin.org/magazine/2025-03/>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 103, Number 7, July 2025, 413-464

<https://www.who.int/publications/journals/bulletin/>

[Reviewed earlier]

Cell

Jun 26, 2025 Volume 188 Issue 13 p3367-3624

<https://www.cell.com/cell/current>

[Reviewed earlier]

Cell and Gene Therapy Insights

May 2025 Issue Volume 11 Issue 4

<https://www.insights.bio/cell-and-gene-therapy-insights/journal/250/volume-11-issue-4>

[Reviewed earlier]

Child Care, Health and Development

Volume 51, Issue 4 July 2025

<https://onlinelibrary.wiley.com/toc/13652214/current>
[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 118, Issue 1 Pages: 1-271 July 2025
<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>
[Reviewed earlier]

Clinical Therapeutics

July 2025 Volume 47 Issue 7 p463-532
<http://www.clinicaltherapeutics.com/current>
[Reviewed earlier]

Clinical Trials

Volume 22 Issue 3, June 2025
<https://journals.sagepub.com/toc/ctja/22/3>
Articles
[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>
[Accessed 19 July 2025]
[No new digest content identified]

Contemporary Clinical Trials

Volume 153 June 2025
<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/153/suppl/C>
[Reviewed earlier]

The CRISPR Journal

Volume 8, Issue 3 / June 2025
<https://www.liebertpub.com/toc/crispr/8/3>
[Reviewed earlier]

Current Genetic Medicine Reports

Volume 13, Issue 1 December 2025
<https://link.springer.com/journal/40142/volumes-and-issues/13-1>
[Reviewed earlier]

Current Medical Research and Opinion

Volume 41, Issue 3 2025
<https://www.tandfonline.com/toc/icmo20/current>
[Reviewed earlier]

Current Opinion in Infectious Diseases

August 2025 - Volume 38 - Issue 4

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 19 July 2025]

[No new digest content identified]

Cytotherapy

July 2025 Volume 27 Issue 7 p791-884

<https://www.isct-cytotherapy.org/current>

Special Issue: The Golden Age of Cell and Gene Therapy

[The Golden Age of Cell and Gene Therapy](#)

Edwin M. Horwitz

Published online: April 09, 2025 p791-794

We are in the midst of an evolutionary change in the practice of medicine. Whereas drugs were the sole agent of treatment in past eras, we now have a robust armamentarium of allogeneic and genetically modified autologous cell therapies to treat many disorders. Cells as a therapeutic agent have the potential to remedy diseased or damaged tissues that drugs simply cannot. Once the purview of academic laboratories and hospitals, many cell and gene therapy products are now commercially available. Cancer immunotherapy has the potential to cure patients with incurable diseases. Patients with recalcitrant rheumatologic disorders have renewed hope for relief. Children with steroid refractory graft-versus-host disease, who have a dismal prognosis, can be treated with off-the-shelf cell therapy. Most exciting, we can now *cure* genetic disorders. Ideas that were once science fiction are now approved, commercially available therapies. While the 20th century was the age of pharmaceuticals, the 21st century is the Golden Age of Cell and Gene Therapy.

Developing World Bioethics

Volume 25, Issue 2 Pages: 81-163 June 2025

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 35, Issue 4, 2025

<https://www.tandfonline.com/toc/cdip20/35/4?nav=tocList>

[Reviewed earlier]

Development Policy Review

Volume 43, Issue 4 July 2025

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 19 - 2025

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 49, Issue 3 July 2025

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

eBioMedicine

Volume 117 July 2025

<https://www.sciencedirect.com/journal/ebiomedicine/vol/117/suppl/C>

[Reviewed earlier]

EMBO Reports

Volume 26 Issue 13 8 July 2025

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 31, Number 7—July 2025

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 51 June 2025

<https://www.sciencedirect.com/journal/epidemics/vol/51/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 153 - 2025

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 47, Issue 3, Pages: 1-45, May–June 2025

<https://onlinelibrary.wiley.com/toc/25782363/current>

Undue inducement :: Deception in research

[Reviewed earlier]

Ethics & International Affairs

Volume 38 - Issue 4 - Winter 2024

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 32 2024

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc>

[Reviewed earlier]

The European Journal of Public Health

Volume 35, Issue 3, June 2025

<https://academic.oup.com/eurpub/issue/35/3>

[Reviewed earlier]

Expert Review of Vaccines

Volume 24, 2025 Issue 1

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

May/June 2025 Volume 104, Number 3

<https://www.foreignaffairs.com/issues/2025/104/3>

[Reviewed earlier]

Forum for Development Studies

Volume 52, 2025 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

The Rebirth of the Global South: Geopolitics, Imageries, and Developmental Realities

[Reviewed earlier]

Frontiers in Genetics

<https://www.frontiersin.org/journals/genetics>

[Accessed 19 July 2025]

Review

Accepted on 18 Jul 2025

[A decade of research on genetic privacy: The Findings of the GetPreCiSe Center at Vanderbilt University](#)

Christopher Slobogin, et al.

Editorial

Accepted on 15 Jul 2025

[Editorial: Expanding Insights Into Structure, Function, and Disorder of Genome by the Power of Artificial Intelligence in Bioinformatics](#)

Hongqiang Lyu, et al.

Frontiers in Genome Editing

<https://www.frontiersin.org/journals/genome-editing>

[Accessed 19 July 2025]

Mini Review

Accepted on 14 Jul 2025

[In Pursuit of an HIV Cure: from Stem Cell Transplants to Gene Therapies](#)

Jennifer Clees, et al.

Frontiers in Medicine

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1463>

[Accessed 19 July 2025]

[No new digest content identified]

Gene Therapy – Nature

Volume 32 Issue 3, May 2025

<https://www.nature.com/gt/volumes/32/issues/3>

[Reviewed earlier]

Genetics in Medicines

Volume 27, Issue 6 June 2025

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/65>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 19 July 2025]

[No new digest content identified]

Global Health Action

Volume 18, Issue 1 (2025)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 12, No. 6 December 20, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 19 July 2025]

[No new digest content identified]

Global Public Health

Volume 20, Issue 1 (2025)
<http://www.tandfonline.com/toc/rgph20/current>
[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>
[Accessed 19 July 2025]
[No new digest content identified]

Health and Human Rights

Volume 26, Issue 2, December 2024
<https://www.hhrjournal.org/volume-26-issue-2-december-2024/>
Special Section: Distress Migration and the Right to Health
[Reviewed earlier]

Health Economics, Policy and Law

Volume 20 - Issue 1 - January 2025
<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>
[Reviewed earlier]

Health Policy and Planning

Volume 40, Issue 5 June 2025
<https://academic.oup.com/heapol/issue/40/5>
[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>
[Accessed 19 July 2025]
[No new digest content identified]

Human Gene Therapy

Volume 36, Issue 13-14 / July 2025
<https://www.liebertpub.com/toc/hum/36/13-14>
[New issue; No digest content identified]

Humanitarian Practice Network

<https://odihpn.org/>
[Accessed 19 July 2025]
Featured Publications
[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 21 Issue 1, 2025
<https://www.tandfonline.com/toc/khvi20/21/1?nav=tocList>

Selected Content
[Reviewed earlier]

Immunity

Jul 08, 2025 Volume 58 Issue 7 p1615-1870
<https://www.cell.com/immunity/current>
[New issue; No digest content identified]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>
[Accessed 19 July 2025]
[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content/>
[Accessed 19 July 2025]
[No new digest content identified]

International Health

Volume 17, Issue 4, July 2025
<https://academic.oup.com/inthealth/issue/17/4>
[Reviewed earlier]

International Human Rights Law Review

Volume 14 (2025): Issue 1 (Jun 2025)
<https://brill.com/view/journals/hrlr/14/1/hrlr.14.issue-1.xml>
[No new digest content identified]

International Journal of Community Medicine and Public Health

Vol. 12 No. 5 (2025): May 2025
<https://www.ijcmph.com/index.php/ijcmph/issue/view/124>
[Reviewed earlier]

International Journal of Epidemiology

Volume 54, Issue 3, June 2025
<https://academic.oup.com/ije/issue/54/3>
[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 18 Issue 2 2025
<https://www.emerald.com/insight/publication/issn/2056-4902/vol/18/iss/2>
Table of contents
[New issue; No digest content identified]]

JAMA

July 15, 2025, Vol 334, No. 3, Pages 193-284

<https://jamanetwork.com/journals/jama/currentissue>

[New issue; No digest content identified]

JAMA Health Forum

July 2025, Vol 6, No. 7

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

JAMA Pediatrics

June 2025, Vol 179, No. 6, Pages 587-688

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JBIR Evidence Synthesis

July 2025 - Volume 23 - Issue 7

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[New issue; No digest content identified]

Journal of Adolescent Health

July 2025 Volume 77 Issue 1 p1-172

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 83 (2025)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

Journal of Bioethical Inquiry

Volume 22, Issue 1 March 2025

<https://link.springer.com/journal/11673/volumes-and-issues/22-1>

[Reviewed earlier]

Journal of Community Health

Volume 50, Issue 3 June 2025

<https://link.springer.com/journal/10900/volumes-and-issues/50-3>

[Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 8 No. 01 (2025)

<https://www.cmro.in/index.php/jcmro/issue/view/91>

[Reviewed earlier]

Journal of Development Economics

Volume 176 September 2025

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/176/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 20 Issue 3, July 2025

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

July 2025 - Volume 79 - 7

<https://jech.bmj.com/content/79/6>

[New issue; No digest content identified]

Journal of Evidence-Based Medicine

Volume 18, Issue 2 June 2025

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 21, Issue 1 (2025)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 36, Number 2, May 2025

<https://muse.jhu.edu/issue/54734>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 27, Issue 3 June 2025

<https://link.springer.com/journal/10903/volumes-and-issues/27-3>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 23, Issue 2 (2025)
<https://www.tandfonline.com/toc/wimm20/current>
[Reviewed earlier]

Journal of International Development

Volume 37, Issue 5 Pages: 1-1193 July 2025
<https://onlinelibrary.wiley.com/toc/10991328/current>
[New issue; No digest content identified]

Journal of Medical Ethics

July 2025 - Volume 51 - 7
<http://jme.bmj.com/content/current>
[New issue; No digest content identified]

Journal of Patient-Centered Research and Reviews

Volume 12, Issue 3 (2025)
<https://institutionalrepository.aah.org/jpcrr/>
[New issue; No digest content identified]

The Journal of Pediatrics

Volume 282 July 2025
<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/282/suppl/C>
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 18, 2025 Issue 1
<https://www.tandfonline.com/toc/jppp20/18/1?nav=tocList>
[Reviewed earlier]

Journal of Public Health Management & Practice

July/August 2025 - Volume 31 - Issue 4
<https://journals.lww.com/jphmp/pages/currenttoc.aspx>
[Reviewed earlier]

Journal of Public Health Policy

Volume 46, Issue 2 June 2025
<https://link.springer.com/journal/41271/volumes-and-issues/46-2>
[Reviewed earlier]

Journal of the Royal Society – Interface

July 2025 Volume 22 Issue 228
<https://royalsocietypublishing.org/toc/rsif/current>
[Reviewed earlier]

Journal of Travel Medicine

Volume 32, Issue 5, July 2025

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 99 • Number 6 • June 2025

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Jul 19, 2025 Volume 406 Number 10500 p203-306

<https://www.thelancet.com/journals/lancet/issue/current>

Editorial

[US health policy: the Senate must act](#)

The Lancet

Comment

[Strengthening global routine childhood vaccination](#)

Hai Fang

Perspectives

Book

[Vaccination: a changing political, scientific, and personal landscape](#)

Heidi Larson

Articles

[Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023](#)

GBD 2023 Vaccine Coverage Collaborators

[The case for optimal investment in combating HIV, tuberculosis, and malaria: a global modelling study](#)

Timothy B Hallett, et al.

[Evaluating the impact of two decades of USAID interventions and projecting the effects of defunding on mortality up to 2030: a retrospective impact evaluation and forecasting analysis](#)

Daniella Medeiros Cavalcanti, et al.

The Lancet Child & Adolescent Health

Aug 2025 Volume 9 Number 8 p519-612, e16

<https://www.thelancet.com/journals/lanchi/issue/current>

The Lancet Child & Adolescent Health Commission

[The Lancet Child & Adolescent Health Commission on the future of neonatology](#)

Daniele De Luca, et al.

Summary

Neonatal mortality remains unacceptably high throughout the world. Survival of sick infants in their first month of life has improved over the past six decades. However, many comorbidities persist, with lifelong implications for health. The current ecosystem for research and development of drugs and medical devices to treat neonatal disorders is hindering further improvements to neonatal outcomes, especially infants born preterm or needing critical care. Innovation is lagging, and this is a public health problem characterised by multifactorial challenges in leadership, collaboration, regulation, funding, and commercial viability. The Lancet Child & Adolescent Health Commission on the future of neonatology was created to consider these challenges and design a roadmap of strategies to accelerate research and development that will innovate and improve health care for neonates. We call for regulatory agencies, governments, funders, industry partners, and clinical researchers from diverse medical fields to invest in effective pathways for drug and medical device development and to unite in responsive and dynamic collaborations with diverse patients, families, and advocacy groups whose engagement in clinical research and advocacy can help neonatologists to achieve the best science and health equity for neonates worldwide, now and in the future.

Lancet Digital Health

Jun 2025 Volume 7 Number 6

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Jul 2025 Volume 13 Number 7 e1151-e1326

<https://www.thelancet.com/journals/langlo/issue/current>

Articles

[**Safety of nOPV2 administered during a supplementary immunisation activity in Uganda, 2022: data triangulation from a prospective cohort event monitoring programme and vaccine safety surveillance reports**](#)

Ashley T Longley, et al.

[**Evidence from two rounds of Population HIV Impact Assessments of progress towards HIV epidemic control in adolescents aged 15–19 years in Eswatini, Lesotho, Malawi, and Zimbabwe: a cross-sectional study**](#)

Chloe A Teasdale, et al.

[**Cost-effective pricing of long-acting injectable HIV pre-exposure prophylaxis for adolescent girls and young women in South Africa: a model-based analysis**](#)

Elena Y Jin, et al.

Lancet Infectious Diseases

Jun 2025 Volume 25 Number 6 p595-700, e316-e369

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Jul 2025 Volume 10 Number 7 e537-e639

<https://www.thelancet.com/journals/lanpub/issue/current>

[New issue; No digest content identified]

Lancet Respiratory Medicine

Jun 2025 Volume 13 Number 6 p473-568, e30-e32
<https://www.thelancet.com/journals/lanres/issue/current>
[Reviewed earlier]

Maternal and Child Health Journal

Volume 29, Issue 6 June 2025
<https://link.springer.com/journal/10995/volumes-and-issues/29-6>
[Reviewed earlier]

Medical Decision Making (MDM)

Volume 45 Issue 5, July 2025
<http://mdm.sagepub.com/content/current>
[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy
Volume 103, Issue 2 Pages: 243-637 June 2025
<https://onlinelibrary.wiley.com/toc/14680009/current>
[Reviewed earlier]

Molecular Therapy

Jul 02, 2025 Volume 33 Issue 7 p2951-3452
<https://www.cell.com/molecular-therapy/current>
[Reviewed earlier]

Nature

Volume 643 Issue 8072, 17 July 2025
<https://www.nature.com/nature/volumes/641/issues/8072>
Editorial 15 Jul 2025

[Without science, there can be no development](#)

A United Nations conference on financing sustainable development was a missed opportunity to fund the science needed to create a better world.

Career Feature 20 Jun 2025

[Africa's chief diplomat for vaccine manufacturing](#)

Virologist Amadou Sall is the driving force behind a world-class manufacturing hub in Senegal.
Abdullahi Tsanni

Nature Biotechnology

Volume 43 Issue 7, July 2025
<https://www.nature.com/nbt/volumes/43/issues/7>
Editorial 15 Jul 2025

[Clinical trials gain intelligence](#)

As governments around the world begin to embrace artificial intelligence in healthcare, clinical trials are entering a new phase — faster, smarter and more inclusive. With regulatory momentum building to adapt new technologies, artificial intelligence is no longer just a promise for the future but a powerful tool reshaping how trials are designed, conducted and analyzed today.

Comment 15 Jul 2025

[Platform solutions for commercial challenges to expanding patient access and making gene editing sustainable](#)

Platform-based approaches for gene-editing therapies could markedly improve development efficiency, reduce costs and increase access for patients with rare diseases. Although gene editing has shown remarkable clinical success for a small number of Mendelian disease indications, broader adoption faces substantial hurdles. We propose strategies to overcome these challenges through modular platforms for nonclinical and chemistry, manufacturing and controls (CMC) data reuse, risk-based manufacturing quality, and streamlined umbrella clinical trials for regulatory efficiency and accelerated approval.

Sadik H. Kassim, Fyodor Urnov, Vanessa Almendro-Navarro

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 19 July 2025)

[Reviewed earlier]

Nature Genetics

Volume 57 Issue 6, June 2025

<https://www.nature.com/ng/volumes/57/issues/6>

[Reviewed earlier]

Nature Human Behaviour

Volume 9 Issue 6, June 2025

<https://www.nature.com/nathumbehav/volumes/9/issues/6>

[Reviewed earlier]

Nature Medicine

Volume 31 Issue 6, June 2025

<https://www.nature.com/nm/volumes/31/issues/6>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 24 Issue 7, July 2025

<https://www.nature.com/nrd/volumes/24/issues/7>

Comment 10 Feb 2025

[A new European platform for advancing regulatory science research](#)

Launching in 2025, the European Platform for Regulatory Science Research will bring together academia, regulators and other stakeholders to accelerate collaborative regulatory science research solutions.

Liese Barbier, Pierpaolo Moscariello, Anna Maria Gerdina Pasmooij

Nature Reviews Genetics

Volume 26 Issue 7, July 2025

<https://www.nature.com/nrg/volumes/26/issues/7>

[Reviewed earlier]

Nature Reviews Immunology

Volume 25 Issue 6, June 2025

<https://www.nature.com/nri/volumes/25/issues/6>

[Reviewed earlier]

New England Journal of Medicine

Volume 393 No. 3 July 17, 2025

<https://www.nejm.org/toc/nejm/medical-journal>

Perspective

[The Role of Public Health Agencies in Creating Vaccine Policy](#)

Author: Peter Marks, M.D., Ph.D.

Published June 25, 2025

DOI: 10.1056/NEJMp2507404

[Included earlier as online first article]

NEJM Evidence

Volume 4 No. 7 July 2025

<https://evidence.nejm.org/toc/evid/current>

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[Reviewed earlier]

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 19 July 2025]

[No new digest content identified]

Pediatrics

Volume 156, Issue 1 July 2025

<https://publications.aap.org/pediatrics/issue/156/1>

[Reviewed earlier]

PharmacoEconomics

Volume 43, Issue 8 August 2025

<https://link.springer.com/journal/40273/volumes-and-issues/43-8>

[New issue; No digest content identified]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 19 July 2025)
[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 19 July 2025)
[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60

(Accessed 19 July 2025)

[Change in influenza vaccine uptake among adults in the United States from May 2020 to October 2024](#)

Hannah Melchinger, Sameer M. Belgaumi, Noreen Ahmed, Saad B. Omer, Aryn A. Malik

Research Article | published 16 Jul 2025 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0004756>

PLoS Medicine

<https://journals.plos.org/plosmedicine/>

(Accessed 19 July 2025)
[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 19 July 2025)
[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 19 July 2025]

[Vaccination readiness and political party preference in Germany: Trust, collective responsibility, and the populist radical right](#)

Kathleen D. Magnus, Niklas Dammann, Daniel Lüdecke

Research Article | published 14 Jul 2025 PLOS ONE

<https://doi.org/10.1371/journal.pone.0328045>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 19 July 2025]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

July 15, 2025 vol. 122 no. 28

<https://www.pnas.org/toc/pnas/122/28>

[New issue; No digest content identified]

PNAS Nexus

Volume 4, Issue 5, May 2025

<https://academic.oup.com/pnasnexus/issue/4/5>

[Reviewed earlier]

Prehospital & Disaster Medicine

Volume 40 - Issue 3 - June 2025

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 197 August 2025

<https://www.sciencedirect.com/journal/preventive-medicine/vol/197/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

July 2025 Volume 292 Issue 2050

<https://royalsocietypublishing.org/toc/rspb/current>

Table of Contents

Special feature: The other 1%: Showcasing science and scientists from the Global South and indigenous communities

The other 1%: Showcasing science and scientists from the Global South and indigenous communities. Guest edited by Sarah Brosnan, Stephanie Meirmans, Maurine Neiman, Guadalupe Peralta and Shalene Singh-Shepherd.

[Reviewed earlier]

Public Health

Volume 244 July 2025

<https://www.sciencedirect.com/journal/public-health/vol/244/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 18, Issue 2, July 2025

<http://phe.oxfordjournals.org/content/current>

Original Articles

Pandemic and Crisis Preparedness and Response: Conceptualizing Cultural, Social and Political Drivers of Trustworthiness and Collective Action

Kristine Bærøe and others

Public Health Genomics

2025, Vol. 28, No. 1

<https://karger.com/phg/issue/28/1>

[Reviewed earlier]

Public Health Reports

Volume 140 Issue 2-3, March-April/May-June 2025

<https://journals.sagepub.com/toc/phrg/140/2-3>

Research article

First published online September 28, 2024

[**Increased Identification of Vaccines for Vaccine Safety Surveillance Through Linkage With the Minnesota Immunization Information Connection as of December 31, 2023**](#)

[Jingyi Zhu, PhD](#)

Qualitative Health Research

Volume 35 Issue 7, June 2025

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

Research Ethics

Volume 21 Issue 3, July 2025

<http://journals.sagepub.com/toc/reab/current>

Editorial

First published online July 16, 2025

[**The politics of research ethics**](#)

[Bridget Haire](#)

Research article

First published online April 23, 2025

[**Equitable payments for research participation: A successful case of exceptionalism**](#)

[Lisa M. Rasmussen et al.](#)

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 19 July 2025]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Latest Articles

[No new digest content identified]

Risk Analysis

Volume 45, Issue 5 Pages: 969-1185 May 2025

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>
[Accessed 19 July 2025]
[No new digest content identified]

Royal Society Open Science

July 2025 Volume 12 Issue 76

<https://royalsocietypublishing.org/toc/rsos/current>
[Reviewed earlier]

Science

Volume 389| Issue 6757| 17 Jul 2025

<https://www.science.org/toc/science/current>

Editorial

[Science philanthropy faces a new reality](#)

BY Adam Falk

17 Jul 2025

Research Articles

[Vaccination to mitigate climate-driven disruptions to malaria control in Madagascar](#)

BY Benjamin L. Rice, et al.

17 Jul 2025

Science and Engineering Ethics

Volume 31, Issue 4 August 2025

<https://link.springer.com/journal/11948/volumes-and-issues/31-4>

[New issue; No digest content identified]

Science Translational Medicine

Volume 17| Issue 807| 16 Jul 2025

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 19 July 2025]

[No new digest content identified]

Social Science & Medicine

Volume 380 September 2025

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/380/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 19 July 2025]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 46, Issue 3 June 2025

<https://link.springer.com/journal/11017/volumes-and-issues/46-3>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 66 July–August 2025

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/66/suppl/C>

Research article Open access

[Knowledge, attitudes, practices and vaccine acceptance towards seasonal influenza vaccination among international travelers: a cross-sectional survey in Thailand](#)

Pathomthep Leowattana, Viravarn Luvira, Noppadon Tangpukdee, Panita Looareesuwan, ... Pornthep Chanthavanich

Article 102863

Tropical Medicine & International Health

Volume 30, Issue 7 Pages: i-iv, 577-748 July 2025

<https://onlinelibrary.wiley.com/toc/13653156/current>

OPINION

[Resurgence of polio and the path to eradication](#)

Ahmed Al-Nusairi, Raveena Bansari, Steven Lippmann

Pages: 577-579

First Published: 05 May 2025

Vaccine

Volume 60 11 July 2025

<https://www.sciencedirect.com/journal/vaccine/vol/60/suppl/C>

[Reviewed earlier]

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 19 July 2025]

Open Access Article

[Coverage and Vaccine Hesitancy of Influenza Vaccination Among Reproductive-Age Women \(18–49 Years Old\) in China: A National Cross-Sectional Study](#)

by Jie Deng, Chenyuan Qin, Min Liu and Jue Liu

Vaccines 2025, 13(7), 752; <https://doi.org/10.3390/vaccines13070752> - 14 Jul 2025

Abstract

Background: Influenza is a significant global respiratory infection, and vaccinating reproductive-age women, particularly in densely populated countries like China, cannot be overlooked. In this study, we aimed to determine influenza vaccination coverage, vaccine hesitancy, as well as associated factors among Chinese women [

Value in Health

July 2025 Volume 28 Issue 7 p979-1140
<https://www.valueinhealthjournal.com/current>
[Reviewed earlier]

World Development

Volume 191 July 2025

<https://www.sciencedirect.com/journal/world-development/vol/191/suppl/C>
[Reviewed earlier]

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Pre-Print Servers

arxiv

<https://arxiv.org/>

[Accessed 19 July 2025]

[Filters: *Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics*]

arXiv:2507.09947 [pdf, html, other]

[Modeling Cholera Dynamics with Vaccination as the Control Strategy and Seasonal-forcing Transmission](#)

Eric Herrison Gyamfi

This study presents a seasonally forced cholera model that incorporates imperfect vaccination as a control strategy. The model captures the temporal dynamics of susceptible, vaccinated, infected, and recovered individuals, as well as the environmental pathogen concentration. A key focus is the instantaneous reproduction number, which serves as a threshold indicator for outbreak persistence or elimination. When reproduction number, the disease-free equilibrium is attainable; otherwise, endemic conditions persist. We conduct a sensitivity analysis to evaluate the influence of two critical parameters: the vaccination rate and the waning rate of immunity. Results show that increasing the vaccination rate and reducing the waning rate significantly decrease reproduction number, reinforcing the importance of sustained vaccine efficacy. Seasonal forcing amplifies the complexity of cholera dynamics, revealing the need for timely public health interventions, especially before high-transmission periods. This model demonstrates practical applicability in informing vaccination strategies, especially in resource-limited settings prone to seasonal outbreaks. It offers a flexible framework for public health planning, adaptable to other waterborne diseases. The findings suggest that integrated approaches combining vaccination, improved sanitation, and targeted education are essential to reducing cholera transmission and achieving long-term control.

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 19 July 2025]

[No new digest content identified]

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 19 July 2025]

[Morbidity, Mortality and Immunization in Severe COVID-19 Among the Elderly in Brazil: A Five-Year Perspective](#)

Silvio Alencar Cândido-Sobrinho, Francisco de Sousa Júnior, José Quirino da Silva-Filho, Vânia Angélica Feitosa Viana, Aldo Ângelo Moreira Lima

medRxiv 2025.05.01.25326813; doi: <https://doi.org/10.1101/2025.05.01.25326813> Revision

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]

[No new digest content identified]

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 19 July 2025]

Research Article Open Access

[Responding to and managing antibiotic shortages: a qualitative study with experts and opinion leaders](#)

[version 1; peer review: awaiting peer review]

Vrinda Nampoothiri, et al.

Abstract

Background

We investigated the current mitigation strategies undertaken in different regions to manage antibiotic shortages through in-depth expert interviews.

Methods

Purposive sampling was used to identify stakeholders with expertise in managing antibiotic supply chains, access, and shortages between August 2023 and April 2024. Consented participants were interviewed using a semi-structured interview guide developed using the PESTELI (political, economic, sociological, ecological, technological, legal, industry) framework. Data collection and analysis were iterative and recursive, using constant comparison.

Results

Participants who were interviewed (n=16) had local, national, and global roles in managing and studying access, supply, and demand chain management from Europe, South Africa, India and USA. Political engagement on antibiotic shortages is reported to facilitate effective mitigation strategies, especially in areas where there is strong evidence of government investment. Legal measures have also been used; for example, pharmacists in the UK being given rights to automatically substitute antibiotics on prescriptions and negotiating with pharmaceutical companies for greater transparency on the challenges in manufacturing. Economic incentives are currently missing and are recognised as being a driver for lack of engagement on this topic from pharmaceutical industry. Greater transparency is required from the pharmaceutical companies on the manufacturing chain issues that may lead to shortages. Technologically there is a major gap in systems to forecast and manage antibiotic shortages. Sociological elements include adopting appropriate communication to not cause panic buying and hoarding by organisations when there is an impending shortage. Legislative changes are

linked to the political and economic barriers for cohesive systems to manage the antibiotic manufacture and supply chain in relation to shortages.

Conclusion

Currently there are limited interventions to respond to and manage shortages. The antibiotic manufacture and supply chain is complex and under influence of PESTELI indicators which will need to be understood and addressed in different contexts and regions.

*

*

*

*

Think Tanks

Brookings [to 19 July 2025]

<http://www.brookings.edu/>

Reports, Events

No new digest content identified.

Center for Global Development [to 19 July 2025]

<https://www.cgdev.org/>

All Research

BRIEF

How Gavi 6.0 Can Take a Bigger Leap

Janeen Madan Keller et al.

July 18, 2025

Gavi's board and leadership must stretch scarce resources to fulfill a challenging double mandate: (1) stabilizing immunization outcomes and fiscal solvency in Gavi-eligible countries facing severe health financing shocks; and (2) laying the groundwork for durable transformation via a radically simp...

Chatham House [to 19 July 2025]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events

No new digest content identified.

Council on Foreign Relations [to 19 July 2025]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

No new digest content identified.

CSIS [to 19 July 2025]

<https://www.csis.org/>

Reports [Selected]

No new digest content identified.

Kaiser Family Foundation [to 19 July 2025]

https://www.kff.org/search/?post_type=press-release

Newsroom

No new digest content identified.

McKinsey Global Institute [to 19 July 2025]

<https://www.mckinsey.com/mgi/overview>

Latest Research

No new digest content identified.

ODI [Overseas Development Institute] [to 19 July 2025]

<https://odi.org/en/publications/>

Publications [Selected]

No new digest content identified.

Pew Research Center [to 19 July 2025]

<https://www.pewresearch.org/>

Latest Publications [Selected]

No new digest content identified.

Rand [to 19 July 2025]

<https://www.rand.org/pubs.html>

Published Research [Selected]

Research Jul 16, 2025

Chinese Engagement with Africa: A RAND Research Primer

The authors present an overview of engagement between African countries and the People's Republic of China since the mid-20th century, including economic, humanitarian, and political aspects; trade and investment flows; and medical and military aid.

Urban Institute [to 19 July 2025]

<https://www.urban.org/publications>

New Research Publications - Selected

World Economic Forum [to 19 July 2025]

<https://agenda.weforum.org/press/>

Media [Selected]

No new digest content identified.

.....

.....

Public Consultations/Call for Inputs/Call for Papers

Draft guideline on the quality aspects of mRNA vaccines

EMA Draft: consultation open **Consultation dates: 31/03/2025 to 30/09/2025**

Reference Number: EMA/CHMP/BWP/82416/2025

Summary:

This guideline addresses the quality aspects of mRNA vaccines. It addresses specific aspects regarding the manufacturing process, characterisation, specifications and analytical control of mRNA vaccines, as well as the definition of starting materials, active substance and finished product for mRNA

vaccines. Additional regulatory considerations are provided for changes in existing mRNA vaccine strains, bivalent and multivalent vaccines, self-amplifying mRNA vaccines, other delivery systems and use of platform technology/prior knowledge. The scope of this guideline is applicable to mRNA vaccines against infectious diseases. Other mRNA-based medicinal products are out of scope of this guideline, although relevant parts of this guideline may be applicable to those. It is not intended to address specific requirements for mRNA vaccines to be used in clinical trials, however the scientific principles described may also be applicable during pharmaceutical development.

* * * *

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

* * * *
* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy ([CVEP](#)) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#) and industry resource members Janssen/J&J, Pfizer, Sanofi US, and GSK. (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*